Search

Your search keyword '"Yang, Tsung-Ying"' showing total 638 results
Start Over Author "Yang, Tsung-Ying"
638 results on '"Yang, Tsung-Ying"'

3. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor[FIGURE DASH]Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

Author

Yang, James Chih-Hsin, Lee, Dae Ho, Lee, Jong-Seok, Fan, Yun, de Marinis, Filippo, Iwama, Eiji, Inoue, Takako, Rodríguez-Cid, Jerónimo, Zhang, Li, Yang, Cheng-Ta, de la Mora Jimenez, Emmanuel, Zhou, Jianying, Pérol, Maurice, Lee, Ki Hyeong, Vicente, David, Ichihara, Eiki, Riely, Gregory J., Luo, Yiwen, Chirovsky, Diana, Pietanza, M. Catherine, Bhagwati, Niyati, Lu, Shun, Joseph Boyer, Michael, Hui, Rina, Wong, Mark, Mant, Andrew, Parente, Phillip, John, Thomas, Parakh, Sagun, Castro, Gilberto, Jr, Werutsky, Gustavo, de Azevedo, Sergio Jobim, Andre Franke, Fabio, De Almeida Rego, Joilda Batista, Martins De Marchi, Pedro Rafael, Dix Junqueira, Gustavo, Maris Peria, Fernanda, Brust, Leandro, Cheema, Parneet, Doherty, Mark, Parmar, Ambika, Menjak, Ines B., Leighl, Natasha B., Agulnik, Jason, Lu, Shun, Han, Zhigang, Cui, Jiuwei, Zhang, Li, Cheng, Ying, Chen, Gongyan, Zhang, Helong, Yao, Yu, Hu, Chengping, Wang, Qiming, Zhang, Xin, Zhang, Yong, Zhou, Jianying, Ying, Kejing, Fan, Yun, Wang, Yan, Wang, Ziping, Feng, Jifeng, Du, YingYing, Wu, Lin, Huang, Cheng, Zhou, Xiangdong, Perol, Maurice, Domont, Julien, Lamour, Corinne, Dutilh, Julien, Oulkhouir, Youssef, Westeel, Virginie, Carmier, Delphine, Coudert, Bruno, Lagrange, Aurelie, Spaeth, Dominique, Ropert, Stanislas, Christoph, Daniel C., Kern, Jens, Kopp, Hans-Georg, Griesinger, Frank, Wiewrodt, Rainer, Wermke, Martin, Wesseler, Claas, Mueller, Annette, Vogel, Gunther, Lee, Victor, James Ho, Chung Man, Oscar Chan, Siu Hong, Hung Lo, Sing, Jonathan Nyaw, Shi Feng, Jacky Li, Yu Chung, Bar, Jair, Gottfried, Maya, Dudnik, Julia, Zer, Alona, Moskovitz, Mor, Wollner, Mirjana, Rotem, Ofer, Shamai, Sivan, Asna, Noam, Kamel, Mhameed, Novello, Silvia, Di Costanzo, Francesco, Doni, Laura, Mazzoni, Francesca, Ferrau, Francesco, de Marinis, Filippo, Tonini, Giuseppe, Galetta, Domenico, Piantedosi, Francovito, Vitiello, Fabiana, Kirita, Keisuke, Yoh, Kiyotaka, Takahashi, Toshiaki, Ohe, Yuichiro, Hattori, Yoshihiro, Okamoto, Isamu, Kurata, Takayasu, Yoshioka, Hiroshige, Saka, Hideo, Oki, Masahide, Kato, Terufumi, Tanaka, Hiroshi, Kumagai, Toru, Inoue, Takako, Hida, Toyoaki, Horio, Yoshitsugu, Teraoka, Shunsuke, Ichihara, Eiki, Kishi, Kazuma, Takaya, Hisashi, Takai, Daiya, Kozuki, Toshiyuki, Kasahara, Kazuo, Tambo, Yuichi, Hosomi, Yukio, Kondo, Masashi, Ichiki, Masao, Takeoka, Hiroaki, de la Mora Jimenez, Emmanuel, Hernandez, Carlos Alberto, Rodriguez Cid, Jeronimo Rafael, Rodriguez, Oscar Gerardo Arrieta, Han, Ji-Youn, Min, Young Joo, Kim, Dong-Wan, Park, Keunchil, Lee, Se-Hoon, Lee, Ki Hyeong, Lee, Jong-Seok, Kang, Jin Hyoung, Lee, Dae Ho, Cho, Eun Kyung, Carcereny, Enric, Lopez, Pilar Garrido, Tarruella, Margarita Majem, Rodriguez, Luis Paz-Ares, Vicente Baz, David, Font, Enriqueta Felip, Cobo-Dols, Manuel, Ekman, Simon, Bergman, Bengt, Ohman, Ronny, Vikstrom, Anders, Yang, Chih-Hsin, Chiu, Chao-Hua, Huang, Hsu-Ching, Yang, Cheng-Ta, Su, Jian, Chang, Gee-Chen, Yang, Tsung-Ying, Hsia, Te-Chun, Su, Wu-Chou, Wu, Shang-Yin, Wang, Chin-Chou, Lee, Kang-Yun, Lin, Sheng-Hao, Lin, Chih-Bin, Lee, Jih-Hsiang, Huang, Chun-Yao, Ahmed, Samreen, Newsom-Davis, Thomas, Baijal, Shobhit, Brock, Juliet, Zaki, Kam, Shamash, Jonathan, Papadatos-Pastos, Dionysis, Jain, Pooja, Jane Mackean, Melanie, Kendall, Stephan DiSean, Anderson, Ian, Costin, Dan, Hall, Richard, Campbell, Nicholas, Khan, Saad, Dowell, Jonathan, Mashru, Sandeep, Menon, Smitha, Raza, Ahmad, Ge, Li, Riely, Gregory J., Seetharamu, Nagashree, Stampleman, Laura, Subramanian, Janakiraman, Wender, Donald B., Natale, Ronald B., Zhu, Viola, Ignatius Ou, Sai-Hong, Sanborn, Rachel, and Evangelist, Makenzi C.

Published
2024
Full Text
View/download PDF

4. First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial

Author

Zhou, Qing, Yu, Yan, Xing, Ligang, Cheng, Ying, Wang, Ying, Pan, Yueyin, Fan, Yun, Shi, Jianhua, Zhang, Guojun, Cui, Jiuwei, Zhou, Jianying, Song, Yong, Zhuang, Wu, Ma, Zhiyong, Hu, Yanping, Li, Gaofeng, Dong, Xiaorong, Feng, Jifeng, Lu, Shun, Wu, Jingxun, Li, Juan, Zhang, Longzhen, Wang, Dong, Xu, Xinhua, Yang, Tsung-Ying, Yang, Nong, Guo, Yubiao, Zhao, Jun, Yao, Yu, Zhong, Diansheng, Xia, Bing, Yang, Cheng-Ta, Zhu, Bo, Sun, Ping, Shim, Byoung Yong, Chen, Yuan, Wang, Zhen, Ahn, Myung-Ju, Wang, Jie, and Wu, Yi-Long

Published
2025
Full Text
View/download PDF

7. Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)

Author

Lee, Chee Khoon, Liao, Bin-Chi, Subramaniam, Shalini, Chiu, Chao-Hua, Mersiades, Antony J., Ho, Chao-Chi, Brown, Chris, Lai, Chun-Liang, Hughes, Brett G.M., Yang, Tsung-Ying, O’Byrne, Ken, Luo, Yung-Hung, Yip, Sonia, Ho, Ching-Liang, Bray, Victoria, Su, Wu-Chou, Moore, Melissa, Feng, Wei-Lien, Bai, Ya-Ying, Ford, Kate, Cummins, Michelle M., Stockler, Martin R., Solomon, Benjamin J., John, Thomas, and Chih-Hsin Yang, James

Published
2025
Full Text
View/download PDF

11. Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutationsSunvozertinib for NSCLC with EGFR Exon20ins

Author

Wang, Mengzhao, Yang, James Chih-Hsin, Mitchell, Paul L, Fang, Jian, Camidge, D Ross, Nian, Weiqi, Chiu, Chao-Hua, Zhou, Jianying, Zhao, Yanqiu, Su, Wu-Chou, Yang, Tsung-Ying, Zhu, Viola W, Millward, Michael, Fan, Yun, Huang, Wen-Tsung, Cheng, Ying, Jiang, Liyan, Brungs, Daniel, Bazhenova, Lyudmila, Lee, Chee Khoon, Gao, Bo, Xu, Yan, Hsu, Wei-Hsun, Zheng, Li, and Janne, Pasi A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Lung Cancer, Clinical Research, Lung, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antibodies, Bispecific, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Exons, Humans, Lung Neoplasms, Mutagenesis, Insertional, Mutation, Protein Kinase Inhibitors, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Epidermal growth factor receptor exon 20 insertion mutations (EGFRexon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to a lack of effective therapy, the prognosis of these patients is typically poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor, showing activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily. The most common drug-related adverse events included diarrhea and skin rash. Antitumor efficacy was observed at the doses of 100 mg and above in patients with EGFRexon20ins NSCLC across different subtypes, with prior amivantamab treatment as well as with baseline brain metastasis. The median duration of response has not been reached.SignificanceWe report the discovery and early clinical development of sunvozertinib, a potential treatment option for the unmet medical need of EGFRexon20ins NSCLC. This article is highlighted in the In This Issue feature, p. 1599.

Published
2022

12. Involvement of a BH3-only apoptosis sensitizer gene Blm-s in hippocampus-mediated mood control

Author

Huang, Pei-Hsin, Yang, Tsung-Ying, Yeh, Chia-Wei, Huang, Sheng-Min, Chang, Ho-Ching, Hung, Yun-Fen, Chu, Wen-Chia, Cho, Kuan-Hung, Lu, Tzu-Pin, Kuo, Po-Hsiu, Lee, Li-Jen, Kuo, Li-Wei, Lien, Cheng-Chang, and Cheng, Hwai-Jong

Subjects
Biological Psychology, Biomedical and Clinical Sciences, Psychology, Brain Disorders, Biotechnology, Mental Health, Genetics, Behavioral and Social Science, Depression, Neurosciences, Underpinning research, Aetiology, 2.1 Biological and endogenous factors, 1.1 Normal biological development and functioning, Mental health, Adult, Animals, Apoptosis, Dentate Gyrus, Hippocampus, Humans, Mice, Neurogenesis, Neurons, Proto-Oncogene Proteins c-bcl-2, RecQ Helicases, Clinical Sciences, Public Health and Health Services, Clinical sciences, Biological psychology
Abstract

Mood disorders are an important public health issue and recent advances in genomic studies have indicated that molecules involved in neurodevelopment are causally related to mood disorders. BLM-s (BCL-2-like molecule, small transcript isoform), a BH3-only proapoptotic BCL-2 family member, mediates apoptosis of postmitotic immature neurons during embryonic cortical development, but its role in the adult brain is unknown. To better understand the physiological role of Blm-s gene in vivo, we generated a Blm-s-knockout (Blm-s-/-) mouse. The Blm-s-/- mice breed normally and exhibit grossly normal development. However, global depletion of Blm-s is highly associated with depression- and anxiety-related behaviors in adult mutant mice with intact learning and memory capacity. Functional magnetic resonance imaging of adult Blm-s-/- mice reveals reduced connectivity mainly in the ventral dentate gyrus (vDG) of the hippocampus with no alteration in the dorsal DG connectivity and in total hippocampal volume. At the cellular level, BLM-s is expressed in DG granule cells (GCs), and Blm-s-/- mice show reduced dendritic complexity and decreased spine density in mature GCs. Electrophysiology study uncovers that mature vGCs in adult Blm-s-/- DG are intrinsically more excitable. Interestingly, certain genetic variants of the human Blm homologue gene (VPS50) are significantly associated with depression traits from publicly resourced UK Biobank data. Taken together, BLM-s is required for the hippocampal mood control function. Loss of BLM-s causes abnormality in the electrophysiology and morphology of GCs and a disrupted vDG neural network, which could underlie Blm-s-null-associated anxiety and depression.

Published
2022

16. Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer

Author

Wang, Chi-Liang, Hsu, Kuo-Hsuan, Chang, Ya-Hsuan, Ho, Chao-Chi, Chiang, Chun-Ju, Chen, Kun-Chieh, Cheung, Yun-Chung, Huang, Pei-Ching, Chen, Yu-Ruei, Chen, Chih-Yi, Hsu, Chung-Ping, Hsia, Jiun-Yi, Chen, Hsuan-Yu, Yang, Shi-Yi, Li, Yao-Jen, Yang, Tsung-Ying, Tseng, Jeng-Sen, Chuang, Cheng-Yen, Hsiung, Chao A., Chen, Yuh-Min, Huang, Ming-Shyan, Yu, Chong-Jen, Chen, Kuan-Yu, Su, Wu-Chou, Chen, Jeremy J.W., Yu, Sung-Liang, Chen, Chien-Jen, Yang, Pan-Chyr, Tsai, Ying-Huang, and Chang, Gee-Chen

Published
2023
Full Text
View/download PDF

23. Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation.

Author

Peng, Mu-Han, Huang, Yen-Hsiang, Hsu, Kuo-Hsuan, Tseng, Jeng-Sen, Lee, Po-Hsin, Chen, Kun-Chieh, Chang, Gee-Chen, and Yang, Tsung-Ying

Subjects
THERAPEUTIC use of antineoplastic agents, RESEARCH funding, TREATMENT effectiveness, CANCER patients, RETROSPECTIVE studies, LUNG cancer, DISEASE relapse, GENETIC mutation, EPIDERMAL growth factor receptors
Abstract

Simple Summary: The objective of this study was to compare the clinical outcomes of osimertinib as a 2nd-line treatment versus as a ≥3rd-line treatment in advanced and recurrent Epidermal Growth Factor Receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M mutations. A total of 158 patients who received osimertinib as sequential treatment were enrolled for final analysis between September 2014 and March 2023. Among these, 99 patients (62.7%) received osimertinib as 2nd-line treatment, while 59 patients (37.3%) were treated with it as ≥3rd-line therapy. We found no significant difference in progression-free survival or overall survival between the two groups. Our findings suggest that osimertinib is not only effective as a 2nd-line therapy but also as a ≥3rd-line treatment, offering promising clinical benefits for advanced and recurrent EGFR-mutant NSCLC patients with acquired T790M mutations. Background/Objectives: Osimertinib is a standard sequential therapy for advanced and recurrent Epidermal Growth Factor Receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with the T790M mutation, following treatment with first- or second-generation EGFR Tyrosine Kinase Inhibitors (TKIs). This study aims to investigate the differences in clinical outcomes between osimertinib as a 2nd-line treatment and as a ≥3rd-line treatment in this patient population. Methods: Between September 2014 and March 2023, we enrolled advanced and recurrent T790M + NSCLC patients who had received osimertinib as sequential treatment for analysis. All patients had previously been treated with gefitinib, erlotinib, or afatinib as first-line therapy. Results: A total of 158 patients who received osimertinib as sequential treatment were included in the final analysis. Of these, 99 patients (62.7%) received osimertinib as a 2nd-line treatment, while 59 patients (37.3%) were treated with osimertinib as ≥3rd-line therapy. The median progression-free survival (PFS) was 10.7 months for the 2nd-line group and 8.9 months for the ≥3rd-line group. The median overall survival (OS) from first-line treatment was 73.2 months in the 2nd-line group and 57.5 months in the ≥3rd-line group. No statistically significant differences in PFS or OS were observed between the two groups. Conclusions: Our research demonstrated that osimertinib is effective not only as a 2nd-line therapy but also as a ≥3rd-line treatment, offering promising clinical benefits for advanced and recurrent EGFR-mutant NSCLC patients with acquired T790M mutations who have developed resistance to first- and second-generation EGFR-TKI therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study.

Author

Girard, Nicolas, primary, Kim, Tae Min, additional, Kim, Hye Ryun, additional, Loong, Herbert H., additional, Shinno, Yuki, additional, Lu, Shun, additional, Fang, Yong, additional, Zhao, Jun, additional, Nishino, Kazumi, additional, Lee, Ki Hyeong, additional, Miao, Liyun, additional, Sakamoto, Tomohiro, additional, Felip, Enriqueta, additional, Yang, Tsung-Ying, additional, Dooms, Christophe Alfons, additional, Tan, Daniel Shao-Weng, additional, Le, Xiuning, additional, Brase, Jan Christoph, additional, Grassi, Paolo, additional, and Goto, Koichi, additional

Published
2024
Full Text
View/download PDF

30. Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia

Author

Blechter, Batel, Wong, Jason Y.Y., Agnes Hsiung, Chao, Hosgood, H.Dean, Yin, Zhihua, Shu, Xiao-Ou, Zhang, Han, Shi, Jianxin, Song, Lei, Song, Minsun, Zheng, Wei, Wang, Zhaoming, Caporaso, Neil, Burdette, Laurie, Yeager, Meredith, Berndt, Sonja I., Teresa Landi, Maria, Chen, Chien-Jen, Chang, Gee-Chen, Hsiao, Chin-Fu, Tsai, Ying-Huang, Chen, Kuan-Yu, Huang, Ming-Shyan, Su, Wu-Chou, Chen, Yuh-Min, Chien, Li-Hsin, Chen, Chung-Hsing, Yang, Tsung-Ying, Wang, Chih-Liang, Hung, Jen-Yu, Lin, Chien-Chung, Perng, Reury-Perng, Chen, Chih-Yi, Chen, Kun-Chieh, Li, Yao-Jen, Yu, Chong-Jen, Chen, Yi-Song, Chen, Ying-Hsiang, Tsai, Fang-Yu, Jie Seow, Wei, Bassig, Bryan A., Hu, Wei, Ji, Bu-Tian, Wu, Wei, Guan, Peng, He, Qincheng, Gao, Yu-Tang, Cai, Qiuyin, Chow, Wong-Ho, Xiang, Yong-Bing, Lin, Dongxin, Wu, Chen, Wu, Yi-Long, Shin, Min-Ho, Hong, Yun-Chul, Matsuo, Keitaro, Chen, Kexin, Pik Wong, Maria, Lu, Daru, Jin, Li, Wang, Jiu-Cun, Seow, Adeline, Wu, Tangchun, Shen, Hongbing, Fraumeni, Joseph F., Yang, Pan-Chyr, Chang, I-Shou, Zhou, Baosen, Chanock, Stephen J., Rothman, Nathaniel, Chatterjee, Nilanjan, and Lan, Qing

Published
2021
Full Text
View/download PDF

33. In Vivo Effect of Halicin on Methicillin-Resistant Staphylococcus aureus -Infected Caenorhabditis elegans and Its Clinical Potential.

Author

Kao, Li-Ting, Yang, Tsung-Ying, Hung, Wei-Chun, Yang, Wei-Te, He, Pu, Chen, Bo-Xuan, Wang, Yu-Chi, Chen, Shiou-Sheng, Lai, Yu-Wei, Wang, Hsian-Yu, and Tseng, Sung-Pin

Subjects
METHICILLIN-resistant staphylococcus aureus, DRUG resistance in bacteria, STAPHYLOCOCCUS aureus infections, HYPOGLYCEMIC agents, CAENORHABDITIS elegans
Abstract

Recently, the high proportion of methicillin-resistant Staphylococcus aureus infections worldwide has highlighted the urgent need for novel antibiotics to combat this crisis. The recent progress in computational techniques for use in health and medicine, especially artificial intelligence (AI), has created new and potential approaches to combat antibiotic-resistant bacteria, such as repurposing existing drugs, optimizing current agents, and designing novel compounds. Halicin was previously used as a diabetic medication, acting as a c-Jun N-terminal protein kinase (JNK) inhibitor, and has recently demonstrated unexpected antibacterial activity. Although previous efforts have highlighted halicin's potential as a promising antibiotic, evidence regarding its effectiveness against clinical strains remains limited, with insufficient proof of its clinical applicability. In this study, we sought to investigate the antibacterial activity of halicin against MRSA clinical strains to validate its clinical applicability, and a C. elegans model infected by MRSA was employed to evaluate the in vivo effect of halicin against MRSA. Our findings revealed the antibacterial activity of halicin against methicillin-resistant S. aureus clinical strains with MICs ranging from 2 to 4 µg/mL. Our study is also the first work to evaluate the in vivo effect of halicin against S. aureus using a C. elegans model, supporting its further development as an antibiotic. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women

Author

Wong, Jason Y.Y., Zhang, Han, Hsiung, Chao A., Shiraishi, Kouya, Yu, Kai, Matsuo, Keitaro, Wong, Maria Pik, Hong, Yun-Chul, Wang, Jiucun, Seow, Wei Jie, Wang, Zhaoming, Song, Minsun, Kim, Hee Nam, Chang, I-Shou, Chatterjee, Nilanjan, Hu, Wei, Wu, Chen, Mitsudomi, Tetsuya, Zheng, Wei, Kim, Jin Hee, Seow, Adeline, Caporaso, Neil E., Shin, Min-Ho, Chung, Lap Ping, An, She-Juan, Wang, Ping, Yang, Yang, Zheng, Hong, Yatabe, Yasushi, Zhang, Xu-Chao, Kim, Young Tae, Cai, Qiuyin, Yin, Zhihua, Kim, Young-Chul, Bassig, Bryan A., Chang, Jiang, Ho, James Chung Man, Ji, Bu-Tian, Daigo, Yataro, Ito, Hidemi, Momozawa, Yukihide, Ashikawa, Kyota, Kamatani, Yoichiro, Honda, Takayuki, Hosgood, H. Dean, Sakamoto, Hiromi, Kunitoh, Hideo, Tsuta, Koji, Watanabe, Shun-ichi, Kubo, Michiaki, Miyagi, Yohei, Nakayama, Haruhiko, Matsumoto, Shingo, Tsuboi, Masahiro, Goto, Koichi, Shi, Jianxin, Song, Lei, Hua, Xing, Takahashi, Atsushi, Goto, Akiteru, Minamiya, Yoshihiro, Shimizu, Kimihiro, Tanaka, Kazumi, Wei, Fusheng, Matsuda, Fumihiko, Su, Jian, Kim, Yeul Hong, Oh, In-Jae, Song, Fengju, Su, Wu-Chou, Chen, Yu-Min, Chang, Gee-Chen, Chen, Kuan-Yu, Huang, Ming-Shyan, Chien, Li-Hsin, Xiang, Yong-Bing, Park, Jae Yong, Kweon, Sun-Seog, Chen, Chien-Jen, Lee, Kyoung-Mu, Blechter, Batel, Li, Haixin, Gao, Yu-Tang, Qian, Biyun, Lu, Daru, Liu, Jianjun, Jeon, Hyo-Sung, Hsiao, Chin-Fu, Sung, Jae Sook, Tsai, Ying-Huang, Jung, Yoo Jin, Guo, Huan, Hu, Zhibin, Wang, Wen-Chang, Chung, Charles C., Burdett, Laurie, Yeager, Meredith, Hutchinson, Amy, Berndt, Sonja I., Wu, Wei, Pang, Herbert, Li, Yuqing, Choi, Jin Eun, Park, Kyong Hwa, Sung, Sook Whan, Liu, Li, Kang, C.H., Zhu, Meng, Chen, Chung-Hsing, Yang, Tsung-Ying, Xu, Jun, Guan, Peng, Tan, Wen, Wang, Chih-Liang, Hsin, Michael, Sit, Ko-Yung, Ho, James, Chen, Ying, Choi, Yi Young, Hung, Jen-Yu, Kim, Jun Suk, Yoon, Ho Il, Lin, Chien-Chung, Park, In Kyu, Xu, Ping, Wang, Yuzhuo, He, Qincheng, Perng, Reury-Perng, Chen, Chih-Yi, Vermeulen, Roel, Wu, Junjie, Lim, Wei-Yen, Chen, Kun-Chieh, Li, Yao-Jen, Li, Jihua, Chen, Hongyan, Yu, Chong-Jen, Jin, Li, Chen, Tzu-Yu, Jiang, Shih-Sheng, Liu, Jie, Yamaji, Taiki, Hicks, Belynda, Wyatt, Kathleen, Li, Shengchao A., Dai, Juncheng, Ma, Hongxia, Jin, Guangfu, Song, Bao, Wang, Zhehai, Cheng, Sensen, Li, Xuelian, Ren, Yangwu, Cui, Ping, Iwasaki, Motoki, Shimazu, Taichi, Tsugane, Shoichiro, Zhu, Junjie, Yang, Kaiyun, Jiang, Gening, Fei, Ke, Wu, Guoping, Lin, Hsien-Chin, Chen, Hui-Ling, Fang, Yao-Huei, Tsai, Fang-Yu, Hsieh, Wan-Shan, Yu, Jinming, Stevens, Victoria L., Laird-Offringa, Ite A., Marconett, Crystal N., Rieswijk, Linda, Chao, Ann, Yang, Pan-Chyr, Shu, Xiao-Ou, Wu, Tangchun, Wu, Y.L., Lin, Dongxin, Chen, Kexin, Zhou, Baosen, Huang, Yun-Chao, Kohno, Takashi, Shen, Hongbing, Chanock, Stephen J., Rothman, Nathaniel, and Lan, Qing

Published
2020
Full Text
View/download PDF

38. Efficacy of cefoperazone/sulbactam for ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and the factors associated with poor outcomes

Author

Chen, Rou-Zhen, primary, Lu, Po-Liang, additional, Yang, Tsung-Ying, additional, Lin, Shang-Yi, additional, Tang, Hung-Jen, additional, Chang, Feng-Yee, additional, Yang, Ya-Sung, additional, Chiang, Tsung-Ta, additional, Wang, Fu-Der, additional, Wu, Ting-Shu, additional, Shie, Shian-Sen, additional, Ho, Mao-Wang, additional, Liu, Jien-Wei, additional, Shi, Zhi-Yuan, additional, Chou, Chia-Hui, additional, and Chuang, Yin-Ching, additional

Published
2024
Full Text
View/download PDF

44. Investigation on Traps Dynamics & Negative Bias Stress in D-Mode GaN-on-Si Power MIS HEMTs Under High-Temperature

Author

Rathaur, Shivendra K., Hieu, Le Trung, Yang, Tsung-Ying, Tsai, Shang Hua, Lin, Wen Yu, Dixit, Abhisek, and Chang, Edward Yi

Abstract

This experimental study investigates the traps dynamics and threshold voltage (VTH) shift mechanism under negative bias temperature stress for the GaN-on-Si Power MIS HEMTs on field plate design structure. Based on the experimental analysis, two distinct activation energies (Ea) have been identified under the specific reverse bias conditions of VGS= -30 V and VDS=0 V in a wide temperature range. Reverse bias stress experiments (up to 10 ks) show a positive VTH shift of ~1.6 V at room temperature due to the inversion of the charges at the interface between the insulator and AlGaN layer, resulting in net negative charge near the gate region. Subsequently, there is a decrease in VTH shift till $125~^{\circ }$ C because of the de-trapping of the inversion charges. This phenomenon shows a strong correlation with a thermally activated activation energy of (E ${_{\text {a}}}~\approx ~0.23$ eV). Further, the shift in ${\mathrm { V}}_{\mathrm { TH}}$ turns negative when the temperature is raised to $175~^{\circ }$ C, indicating the accumulation of electrons in the channel layer with activation energy (E ${_{\text {a}}}~\approx ~0.78$ eV) attributed to the activation of nitrogen interstitials from the GaN buffer layer. Additionally, the recovery (up to 10 ks) behavior demonstrates the exponential-linear settlement of the traps to recover the ${\mathrm { V}}_{\mathrm { TH}}$ shift. Moreover, nitrogen interstitials take more time to suppress the threshold voltage instabilities. These findings explain the ${\mathrm { V}}_{\mathrm { TH}}$ shift mechanisms in GaN-on-Si Power MIS HEMTs under NBTI.

Published
2024
Full Text
View/download PDF

46. Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib

Author

Wu, Jia-Jun, primary, Tseng, Jeng-Sen, additional, Zheng, Zhe-Rong, additional, Chu, Cheng-Hsiang, additional, Chen, Kun-Chieh, additional, Lin, Mong-Wei, additional, Huang, Yen-Hsiang, additional, Hsu, Kuo-Hsuan, additional, Yang, Tsung-Ying, additional, Yu, Sung-Liang, additional, Chen, Jin-Shing, additional, Ho, Chao-Chi, additional, and Chang, Gee-Chen, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results